155690-79-2

Basic information

• Product Name: 6-BROMOPYRIDO[2,3-D]PYRIMIDIN-4(1H)-ONE
• Synonyms: 6-BROMOPYRIDO[2,3-D]PYRIMIDIN-4(1H)-ONE;6-BroMo-3H-pyrido[2,3-d]p...;6-BroMo-3H-pyrido[2,3-d]pyriMidin-4-one;6-bromo-3H,4H-pyrido[2,3-d]pyrimidin-4-one;6-bromopyrido[2,3-d]pyrimidin-4(3H)-one;6-Bromo-1H-pyrido[2,3-d]pyrimidin-4-one;6-Bromopyrido[2,3-d]pyrimidin-4(1H)
• CAS NO: 155690-79-2
• Molecular Formula: C₇H₄BrN₃O
• Molecular Weight: 226.04
• Mol File: 155690-79-2.mol

Chemical Properties

• Boiling Point: 396 °C at 760 mmHg
• Flash Point: 193.3 °C
• Appearance: /
• Density: 2.01 g/cm³
• Vapor Pressure: 1.76E-06mmHg at 25°C
• Refractive Index: 1.785
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.20±0.20(Predicted)
• CAS DataBase Reference: 6-BROMOPYRIDO[2,3-D]PYRIMIDIN-4(1H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMOPYRIDO[2,3-D]PYRIMIDIN-4(1H)-ONE(155690-79-2)
• EPA Substance Registry System: 6-BROMOPYRIDO[2,3-D]PYRIMIDIN-4(1H)-ONE(155690-79-2)

Safety Data

• Hazardous Substances Data: 155690-79-2(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
6-BROMOPYRIDO[2,3-D]PYRIMIDIN-4(1H)-ONE is used as a research compound for the study of its chemical properties and potential applications in various fields.
Used in Pharmaceutical Development:
6-BROMOPYRIDO[2,3-D]PYRIMIDIN-4(1H)-ONE is used as a key intermediate in the synthesis of new pharmaceuticals, particularly in the development of novel drug candidates with potential therapeutic applications. Its unique chemical structure allows for further modification and optimization to enhance its pharmacological properties.

InChI:InChI=1/C7H4BrN3O/c8-4-1-5-6(9-2-4)10-3-11-7(5)12/h1-3H,(H,9,10,11,12)

Upstream product

• 3473-63-0 formamidine acetic acid 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 52833-94-0 2-amino-5-bromonicotinicacid 
• 77287-34-4 formamide 
• 1121633-45-1 6-bromopyrido[2,3-d]pyrimidin-4-amine 
• 13362-26-0 2-aminopyridine-3-carboxylic acid ethyl ester 
• 433226-06-3 2-amino-5-bromonicotinic acid ethyl ester 
• 5345-47-1 2-aminopyridin-3-carboxylic acid 

Downstream Products

• 1394930-41-6 C₂₈H₂₉Cl₂FN₆O₃ 
• 1394930-43-8 C₂₃H₂₁Cl₂FN₆O 
• 1394930-38-1 6-bromo-3-[1-(2,6-dichloro-3-fluorophenyl)ethyl]-3H,4H-pyrido[2,3-d]pyrimidin-4-one 
• 1215787-31-7 6-bromo-4-chloropyrido[2,3-d]pyrimidine 
• 1121633-45-1 6-bromopyrido[2,3-d]pyrimidin-4-amine 

Relevant articles and documents

SYNTHESIS, X-RAY STRUCTURE ANALYSIS, AND VIBRATIONAL SPECTRAL STUDIES OF 1-(3-((6-BROMOPYRIDO[2,3-d]PYRIMIDIN-4-YL) OXY)PHENYL)-3-CYCLOPENTYLUREA

Abstract: A new pyrido[2,3-d]pyrimidine derivative 1-(3-((6-bromopyrido[2,3-d]pyrimidin-4-yl)oxy)phenyl)-3-cyclopentylurea is designed and synthesized. The final structure is characterized by 1H, 13C, and 2D NMR, MS, FTIR. In addition, the crystal structure of the title compound is determined by X-ray diffraction. With the 6-311G(2d,p) basis set, the molecule is further explored using density functional theory (DFT) by the B3LYP method. The final results show that the DFT optimized structure of the title molecule is consistent with the crystal structure determined by X-ray diffraction. The Hirshfeld surface analysis and the 2D fingerprint plot are given to support the quantitative analysis of intermolecular interactions and contacts generated by supramolecular accumulation in crystals. The interactions of the title molecule are analyzed by the natural bond orbital analysis. Finally, the molecular electrostatic potential and frontier molecular orbitals are further investigated using DFT. [Figure not available: see fulltext.]

Pyrido[2,3-d]pyrimidine compound as well as preparation method and application thereof

The present invention discloses a pyrido[2,3-d]pyrimidine compound represented by a general formula I or a pharmaceutically acceptable salt thereof. The general formula I is shown as the specification, wherein R1 is selected from one of an alkylamine group of C1-C6, an alicyclic amine group of C1-C6, a heterocyclic amine group of C1-C6, and an aromatic amine group of C6-C8, and X represents a hydrogen atom or a halogen atom. According to the invention, in-vitro cell activity tests prove that the compound provided by the invention has antitumor activity and can be used for preparing medicines for treating and/or preventing various cancers caused by BRaf kinase mutation, such as melanoma, thyroid cancer, breast cancer, liver cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, etc.

Synthesis and antitumor activity of novel pyridino[2,3-d]pyrimidine urea derivatives

A series of novel N-(3-((6-bromopyrido[2,3-d]pyrimidin-4-yl)oxy)phenyl)pyrrolidine-1-carboxamide and 1-(3-((6-bromopyrido[2,3-d]pyrimidin-4-yl)oxy)phenyl)-3-propylurea derivatives were synthesized. Their antitumor activities against human breast carcinoma cells (MCF-7) and human colon cancer cells (HCT-116) in vitro were evaluated, using sorafenib as a positive control drug. Anticancer bioassays indicated that several compounds exhibited appreciable anticancer activity against MCF-7 and HCT-116 cells. Particularly, compounds 9g and 8b demonstrated the most significant inhibitory effect against HCT-116 and MCF-7 cells, with inhibition ratios of 25.56% and 26.46%, respectively. Additionally, the synthesized pyridine[2,3-d]pyrimidine derivatives containing a urea group moieties exhibited antitumor activities against MCF-7 and HCT-116 cells in vitro.

Synthesis, Crystal Structure, and DFT Study of a New Derivative of Pyrido[2,3-d]pyrimidine

Abstract: N-{4-[(6-bromopyrido[2,3-d]pyrimidin-4-yl)oxy]phenyl}morpholine-4-carboxamide has been synthesized as a derivative of pyrido[2,3-d]pyrimidine that demonstrates antitumor, antibacterial, anti-inflammatory, and antimicrobial activities. Synthesis of the target compound based on 2-aminonicotinic acid as the starting material has included its esterification, bromination, cyclization, and substitution reactions. Structure of the product is confirmed by 1H and 13C NMR, FT-IR, and single-crystal X-ray diffraction (XRD). The optimized structure, electrostatic potential and frontier molecular orbitals (FMO) of the compound have been approached by DFT calculations. The compound demonstrates antiproliferative activity on A375 cells.

BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES

The present invention relates to novel Bicyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, Z, R1 R5, R6, and R7 are as defined herein. The present invention also relates to compositions comprising

PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS

The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3 (hereinafter P2X3 inhibitors); particularly the invention relates to compounds that are pyridopyrimidines derivatives, methods of preparing such compounds, ph

COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION

The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.

Pharmacophore requirements for HIV-1 reverse transcriptase inhibitors that selectively “Freeze” the pre-translocated complex during the polymerization catalytic cycle

Reverse transcriptase (RT) is responsible for replicating the HIV-1 genome and is a validated therapeutic target for the treatment of HIV infections. During each cycle of the RT-catalyzed DNA polymerization process, inorganic pyrophosphate is released as the by-product of nucleotide incorporation. Small molecules were identified that act as bioisosteres of pyrophosphate and can selectively freeze the catalytic cycle of HIV-1 RT at the pre-translocated stage of the DNA- or RNA-template-primer-enzyme complex.

Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor

Three series of novel quinazoline and pyrido[2,3-d]pyrimidine derivatives were designed, synthesized and evaluated for their ability to inhibit EGFR tyrosine kinase and a panel of five human cancer cell lines (MCF-7, A549, BT-474, SK-BR-3, and MDA-MB-231)

2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE

The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.